Novavax, COVID and European Commission
Novavax Gets EU Authorization for Updated COVID Vaccine Targeting JN.1 Strain
(Reuters) -The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, the company said on Wednesday. The authorization is for use in individuals 12 years of age and older.
Novavax Is Here for the COVID Fight: What to Know About the Vaccine
In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season.
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant,
EU gives marketing authorization for Novavax updated 2024-2025 Nuvaxovid COVID vaccine
Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that the European Commission has granted Marketing Authorization
Novavax Gets European Approval for Updated Covid Vaccine
Novavax said the European Commission has granted marketing authorization for its updated Covid-19 vaccine.
Canada not ordering Novavax protein-based COVID vaccine this year due to low demand
TORONTO — The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing lack of demand. It says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.
Novavax Says EU Grants Marketing Authorization For Updated 2024-2025 Nuvaxovid COVID-19 Vaccine
Novavax, Inc. (NVAX) announced Wednesday that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025
Buy Rating Affirmed for Novavax Amid Strategic Alliances and Promising Vaccine Trials
Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...
Zacks.com on MSN2d
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a ...
Novavax: Lack Of Sustainable Revenue Growth Is A Problem
Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...
devdiscourse3d
Health News Highlights: From Gerresheimer's Stock Surge to Novavax's EU Authorization
This health news roundup covers various topics including Gerresheimer's stock jump due to an activist investor, a US list of ...
Novavax's Updated 2024-2025 Nuvaxovid(TM) COVID-19 Vaccine Receives Authorization in the EU
Novavax's vaccine is also authorized for use in the U.S., and is in line with guidance from the U.S. Food and Drug ...
Novavax Inc (NVAX) Q2 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
Novavax Inc (NVAX) reports significant revenue from Sanofi partnership and outlines strategic shifts to enhance future growth ...
Benzinga.com4d
What's Going On With Novavax Stock Today?
Novavax says the European Commission granted Marketing Authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine. NVX-CoV2705 is an updated version of Novavax's prototype COVID-19 vaccine ...
Novavax Inc. stock rises Tuesday, still underperforms market
Shares of Novavax Inc. NVAX inched 0.15% higher to $13.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.45% ...